Developing innovative therapies to address unmet needs
Initiatives to combat neglected tropical diseases (NTDs)
Contributing to the GHIT Fund
Many funds are being set up worldwide to advance research into new antibiotics. In Japan, the not-for-proﬁt GHIT Fund was established in 2013 to promote collaboration with overseas partners and provide research funding.
Shionogi has been a contributor since it was founded. In addition to contributing to the GHIT Fund, we also have received funding. Under the auspices of the fund, Shionogi is actively working to eliminate the threat not just of NTDs but infectious diseases in general, including by taking part in a program to discover candidate compounds to treat leishmaniasis and Chagas disease.
Participation in DNDi (Drugs for Neglected Diseases initiative) drug discovery consortium
Together with several other pharmaceutical companies, Shionogi has been a participant in the DNDi’s “Neglected Tropical Diseases Drug Discovery Booster” consortium since its establishment in 2015.
This consortium is an attempt to accelerate drug discovery for the world’s most neglected diseases—leishmaniasis and Chagas disease—and also reduce associated costs. The consortium has started several screening projects for the parasites that cause leishmaniasis and Chagas disease, and most have discovered promising compounds with improved antiparasitic effects. Already, each project has reduced the costs of synthesizing compounds by tens of thousands of dollars and shortened the drug discovery period by roughly 50–70%. In recognition of these achievements, the consortium received the DNDi Project of the Year Award for 2016.